Direct drive heavy-ion-beam inertial fusion at high coupling efficiency

Issues with coupling efficiency, beam illumination symmetry, and Rayleigh-Taylor instability are discussed for spherical heavy-ion-beam-driven targets with and without hohlraums. Efficient coupling of heavy-ion beams to compress direct-drive inertial fusion targets without hohlraums is found to require ion range increasing several-fold during the drive pulse. One-dimensional implosion calculations using the LASNEX inertial confinement fusion target physics code shows the ion range increasing fourfold during the drive pulse to keep ion energy deposition following closely behind the imploding ablation front, resulting in high coupling efficiencies (shell kinetic energy/incident beam energy of 16% to 18%). Ways to increase beam ion range while mitigating Rayleigh-Taylor instabilities are discussed for future work

Utility of the US National Ignition Facility for Development of Inertial Fusion Energy

The demonstration of inertial fusion ignition and gain in the proposed US National Ignition Facility (NIF), along with the parallel demonstration of the feasibility of an efficient, high-repetition-rate driver, would provide the basis for a follow-on Engineering Test Facility (ETF), a facility for integrated testing of the technologies needed for inertial fusion-energy (IFE) power plants. A workshop was convened at the University of California, Berkeley on February 22--24, 1994, attended by 61 participants from 17 US organizations, to identify possible NIF experiments relevant to IFE. We considered experiments in four IFE areas: Target physics, target chamber dynamics, fusion power ethnology, and target systems, as defined in the following sections

Baryon polarization in low-energy unpolarized meson-baryon scattering

We compute the polarization of the final-state baryon, in its rest frame, in low-energy meson--baryon scattering with unpolarized initial state, in Unitarized BChPT. Free parameters are determined by fitting total and differential cross-section data (and spin-asymmetry or polarization data if available) for $pK^-$, $pK^+$ and $p\pi^+$ scattering. We also compare our results with those of leading-order BChPT

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

<p>Abstract</p> <p>Background</p> <p>Several randomized trials have indicated that combination chemotherapy applied in metastatic colorectal cancer (mCRC) does not significantly improve overall survival when compared to the sequential use of cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies.</p> <p>Methods/Design</p> <p>The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer. Patients with unresectable metastatic colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, will be assigned in a 1:1 ratio to receive either capecitabine 1250 mg/m²bid for 14d (d1-14) plus bevacizumab 7.5 mg/kg (d1) q3w (Arm A) or capecitabine 800 mg/m²BID for 14d (d1-14), irinotecan 200 mg/m²(d1) and bevacizumab 7.5 mg/kg (d1) q3w (Arm B). Patients included into this trial are required to consent to the analysis of tumour tissue and blood for translational investigations. In Arm A, treatment escalation from Cape-Bev to CAPIRI-Bev is recommended in case of progressive disease (PD). In Arm B, de-escalation from CAPIRI-Bev to Cape-Bev is possible after 6 months of treatment or in case of irinotecan-associated toxicity. Re-escalation to CAPIRI-Bev after PD is possible. The primary endpoint is time to failure of strategy (TFS). Secondary endpoints are overall response rate (ORR), overall survival, progression-free survival, safety and quality of life.</p> <p>Conclusion</p> <p>The AIO KRK 0110 trial is designed for patients with disseminated, but asymptomatic mCRC who are not potential candidates for surgical resection of metastasis. Two bevacizumab-based strategies are compared: one starting as single-agent chemotherapy (Cape-Bev) allowing escalation to CAPIRI-Bev and another starting with combination chemotherapy (CAPIRI-Bev) and allowing de-escalation to Cape-Bev and subsequent re-escalation if necessary.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov Identifier <a href="http://www.clinicaltrials.gov/ct2/show/NCT01249638">NCT01249638</a></p> <p>EudraCT-No.: 2009-013099-38</p

On the Portability of Generalized Schnorr Proofs

All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately